TY - JOUR
T1 - Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection
T2 - 24-Week results of the VIKING study
AU - Eron, Joseph J.
AU - Clotet, Bonaventura
AU - Durant, Jacques
AU - Katlama, Christine
AU - Kumar, Princy
AU - Lazzarin, Adriano
AU - Poizot-Martin, Isabelle
AU - Richmond, Gary
AU - Soriano, Vincent
AU - Ait-Khaled, Mounir
AU - Fujiwara, Tamio
AU - Huang, Jenny
AU - Min, Sherene
AU - Vavro, Cindy
AU - Yeo, Jane
AU - Walmsley, Sharon L.
AU - Cox, Joseph
AU - Reynes, Jacques
AU - Morlat, Philippe
AU - Vittecoq, Daniel
AU - Livrozet, Jean Michel
AU - Fernández, Pompeyo Viciana
AU - Gatell, Jose M.
AU - DeJesus, Edwin
AU - DeVente, Jerome
AU - Lalezari, Jacob P.
AU - McCurdy, Lewis H.
AU - Sloan, Louis A.
AU - Young, Benjamin
AU - LaMarca, Anthony
AU - Hawkins, Trevor
PY - 2013/3/1
Y1 - 2013/3/1
N2 - Background. Dolutegravir (DTG; S/GSK1349572), a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, has limited cross-resistance to raltegravir (RAL) and elvitegravir in vitro. This phase IIb study assessed the activity of DTG in HIV-1-infected subjects with genotypic evidence of RAL resistance.Methods. Subjects received DTG 50 mg once daily (cohort I) or 50 mg twice daily (cohort II) while continuing a failing regimen (without RAL) through day 10, after which the background regimen was optimized, when feasible, for cohort I, and at least 1 fully active drug was mandated for cohort II. The primary efficacy end point was the proportion of subjects on day 11 in whom the plasma HIV-1 RNA load decreased by ≥0.7 log10 copies/mL from baseline or was
AB - Background. Dolutegravir (DTG; S/GSK1349572), a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, has limited cross-resistance to raltegravir (RAL) and elvitegravir in vitro. This phase IIb study assessed the activity of DTG in HIV-1-infected subjects with genotypic evidence of RAL resistance.Methods. Subjects received DTG 50 mg once daily (cohort I) or 50 mg twice daily (cohort II) while continuing a failing regimen (without RAL) through day 10, after which the background regimen was optimized, when feasible, for cohort I, and at least 1 fully active drug was mandated for cohort II. The primary efficacy end point was the proportion of subjects on day 11 in whom the plasma HIV-1 RNA load decreased by ≥0.7 log10 copies/mL from baseline or was
KW - Dolutegravir
KW - DTG
KW - integrase inhibitor
KW - raltegravir resistance
KW - S/GSK1349572
UR - http://www.scopus.com/inward/record.url?scp=84873633830&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84873633830&partnerID=8YFLogxK
U2 - 10.1093/infdis/jis750
DO - 10.1093/infdis/jis750
M3 - Article
C2 - 23225901
AN - SCOPUS:84873633830
VL - 207
SP - 740
EP - 748
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 5
ER -